Cargando…

Patterns of Use and Outcomes in Patients Treated with Etravirine in the HIV Research Network

This observational analysis examined the clinical outcomes of patients receiving etravirine-(ETR-) based therapy, particularly with protease inhibitors (PIs) other than darunavir (DRV) and with raltegravir (RAL). Data included treatment-experienced adults in the HIV Research Network who began ETR-co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gebo, Kelly, Voss, Cindy, Mrus, Joseph, HIV Research Network
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2013
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3603589/ https://www.ncbi.nlm.nih.gov/pubmed/23533731 http://dx.doi.org/10.1155/2013/492831

Ejemplares similares

Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1–Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial
por: Kakuda, Thomas, et al.
Publicado: (2012)

Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients
por: Orrell, Catherine, et al.
Publicado: (2015)

Profile of etravirine for the treatment of HIV infection
por: Tseng, Alice, et al.
Publicado: (2010)

Etravirine Pharmacokinetics in HIV-Infected Pregnant Women
por: Mulligan, Nikki, et al.
Publicado: (2016)

Etravirine in treatment-experienced HIV-1-infected children 1 year to less than 6 years of age
por: MacBrayne, Christine E., et al.
Publicado: (2021)

The role of etravirine in the management of treatment-experienced pediatric patients with HIV
por: Osterholzer, Danielle
Publicado: (2013)

2520. Resource utilization in adolescents and young adults with HIV in the HIV Research Network
por: Neilan, Anne M, et al.
Publicado: (2019)

Etravirine (TMC-125): The evidence for its place in the treatment of HIV-1 infection
por: Stellbrink, Hans-Jürgen
Publicado: (2010)

Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants
por: Moore, Katy, et al.
Publicado: (2022)

Outcomes of etravirine-based antiretroviral treatment in treatment-experienced children and adolescents living with HIV in Europe and Thailand
por: Lyons, Alex, et al.
Publicado: (2022)

Building capacity for clinical research in developing countries: the INDOX cancer research network experience
por: Ali, Raghib, et al.
Publicado: (2012)

Impact of etravirine on hospitalization rate between 2005 and 2011 among heavily treated HIV-1-infected individuals on failing regimens
por: Potard, Valérie, et al.
Publicado: (2018)

Real-World Experience with Dolutegravir-Based Two-Drug Regimens
por: Ward, Douglas, et al.
Publicado: (2020)

Efficacy and safety of darunavir and etravirine in an antiretroviral multi-experienced youth with vertically HIV-1 infection
por: Rosso, R, et al.
Publicado: (2009)

Etravirine as a Switching Option for Patients with HIV RNA Suppression: A Review of Recent Trials
por: Nelson, Mark, et al.
Publicado: (2014)

Impact of etravirine use on hospitalization rates among highly pre-treated failing HIV-1 infected individuals between 2005 and 2011
por: Lacombe, Jean-Marc, et al.
Publicado: (2014)

The COvid-19 Vascular sERvice (COVER) Study: An International Vascular and Endovascular Research Network (VERN) Collaborative Study Assessing the Provision, Practice, and Outcomes of Vascular Surgery During the COVID-19 Pandemic
por: The Vascular and Endovascular Research Network (VERN) Executive Committee
Publicado: (2020)

Decreased Phenotypic Susceptibility to Etravirine in Patients with Predicted Genotypic Sensitivity
por: Agneskog, Eva, et al.
Publicado: (2014)

Experimental data of co-crystals of Etravirine and L-tartaric acid
por: Rekdal, Mikal, et al.
Publicado: (2017)

Efficacy and tolerability of Etravirine in HIV-1 adult patients: Results of a large French prospective cohort
por: Allavena, Clotilde, et al.
Publicado: (2014)

A clinical and pharmacokinetic study of the combination of etravirine plus raltegravir in HIV patients with expanded intolerance or resistance
por: Bañón, Sara, et al.
Publicado: (2014)

Switching to dual therapy with darunavir/ritonavir and etravirine: a simplification strategy
por: Tyrer, M, et al.
Publicado: (2010)

Rilpivirine versus etravirine validity in NNRTI-based treatment failure in Thailand
por: Teeranaipong, Phairote, et al.
Publicado: (2014)

Electrophysiological Predictors of Clinical Outcome in Traumatic Neuropathies: A Multicenter Prospective Study
por: Ciaramitaro, Palma, et al.
Publicado: (2016)

Clinical and Virological Efficacy of Etravirine Plus Two Active Nucleos(t)ide Analogs in an Heterogeneous HIV-Infected Population
por: López-Cortés, Luis F., et al.
Publicado: (2014)

Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis
por: Tommasi, Chiara, et al.
Publicado: (2011)

Development of a practical synthesis of etravirine via a microwave-promoted amination
por: Feng, Da, et al.
Publicado: (2018)

Repositioning of Etravirine as a Potential CK1ε Inhibitor by Virtual Screening
por: Córdova-Bahena, Luis, et al.
Publicado: (2021)

Efficacy and safety of etravirine-containing regimens in a large cohort of HIV/HCV coinfected patients according to liver fibrosis
por: Luis Casado, Jose, et al.
Publicado: (2014)

Racial inequities in HIV
por: The Lancet HIV
Publicado: (2020)

Pattern and quality of care of cancer pain management. Results from the Cancer Pain Outcome Research Study Group
por: Apolone, G, et al.
Publicado: (2009)

Impact of HIV/AIDS on care and outcomes of severe sepsis
por: Mrus, Joseph M, et al.
Publicado: (2005)

Keeping HIV on the political agenda
por: The Lancet HIV
Publicado: (2022)

Funding the future of the HIV response
por: The Lancet HIV
Publicado: (2022)

Dual therapy with darunavir/r plus etravirine is safe and effective as switching therapy in antiretroviral experienced HIV-patients. The BITER Study
por: Portilla, Joaquín, et al.
Publicado: (2014)

Role of etravirine in the management of treatment-experienced patients with human immunodeficiency virus type 1
por: Viani, Rolando M
Publicado: (2010)

Efficacy of a dual therapy based on darunavir/ritonavir and etravirine in ART-experienced patients
por: Ignacio Bernardino, Jose, et al.
Publicado: (2014)

Interaction between Darunavir and Etravirine Is Partly Mediated by CYP3A5 Polymorphism
por: Belkhir, Leïla, et al.
Publicado: (2016)

Cancer metastasis networks and the prediction of progression patterns
por: Chen, L L, et al.
Publicado: (2009)

Keeping a tenuous grasp on HIV gains
por: The Lancet HIV
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1t0bgmr8lsb8shkhv9e8ijeaf7